TY - JOUR
T1 - Monitoring Temporal Changes in SARS-CoV-2 Spike Antibody Levels and Variant-Specific Risk for Infection, Dominican Republic, March 2021-August 2022
AU - Nilles, Eric J.
AU - de St. Aubin, Michael
AU - Dumas, Devan
AU - Duke, William
AU - Etienne, Marie Caroline
AU - Abdalla, Gabriela
AU - Jarolim, Petr
AU - Oasan, Timothy
AU - Garnier, Salome
AU - Iihoshi, Naomi
AU - Lopez, Beatriz
AU - de la Cruz, Lucia
AU - Puello, Yosanly Cornelio
AU - Baldwin, Margaret
AU - Roberts, Kathryn W.
AU - Peña, Farah
AU - Durski, Kara
AU - Sanchez, Isaac Miguel
AU - Gunter, Sarah M.
AU - Kneubehl, Alexander R.
AU - Murray, Kristy O.
AU - Lino, Allison
AU - Strobel, Sarah
AU - Baez, Amado Alejandro
AU - Lau, Colleen L.
AU - Kucharski, Adam
AU - Gutiérrez, Emily Zielinski
AU - Skewes-Ramm, Ronald
AU - Vasquez, Marietta
AU - Paulino, Cecilia Then
N1 - Publisher Copyright:
© 2023 Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2023/4
Y1 - 2023/4
N2 - To assess changes in SARS-CoV-2 spike binding antibody prevalence in the Dominican Republic and implications for immunologic protection against variants of concern, we prospectively enrolled 2,300 patients with undifferentiated febrile illnesses in a study during March 2021-August 2022. We tested serum samples for spike antibodies and tested nasopharyngeal samples for acute SARS-CoV-2 infection using a reverse transcription PCR nucleic acid amplification test. Geometric mean spike antibody titers increased from 6.6 (95% CI 5.1-8.7) binding antibody units (BAU)/mL during March-June 2021 to 1,332 (95% CI 1,055-1,682) BAU/mL during May- August 2022. Multivariable binomial odds ratios for acute infection were 0.55 (95% CI 0.40-0.74), 0.38 (95% CI 0.27-0.55), and 0.27 (95% CI 0.18-0.40) for the second, third, and fourth versus the first anti-spike quartile; findings were similar by viral strain. Combining serologic and virologic screening might enable monitoring of discrete population immunologic markers and their implications for emergent variant transmission.
AB - To assess changes in SARS-CoV-2 spike binding antibody prevalence in the Dominican Republic and implications for immunologic protection against variants of concern, we prospectively enrolled 2,300 patients with undifferentiated febrile illnesses in a study during March 2021-August 2022. We tested serum samples for spike antibodies and tested nasopharyngeal samples for acute SARS-CoV-2 infection using a reverse transcription PCR nucleic acid amplification test. Geometric mean spike antibody titers increased from 6.6 (95% CI 5.1-8.7) binding antibody units (BAU)/mL during March-June 2021 to 1,332 (95% CI 1,055-1,682) BAU/mL during May- August 2022. Multivariable binomial odds ratios for acute infection were 0.55 (95% CI 0.40-0.74), 0.38 (95% CI 0.27-0.55), and 0.27 (95% CI 0.18-0.40) for the second, third, and fourth versus the first anti-spike quartile; findings were similar by viral strain. Combining serologic and virologic screening might enable monitoring of discrete population immunologic markers and their implications for emergent variant transmission.
UR - http://www.scopus.com/inward/record.url?scp=85150729452&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85150729452&partnerID=8YFLogxK
U2 - 10.3201/eid2904.221628
DO - 10.3201/eid2904.221628
M3 - Article
C2 - 36848869
AN - SCOPUS:85150729452
SN - 1080-6040
VL - 29
SP - 723
EP - 733
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 4
ER -
